Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects
by
Sevy S, Papadimitriou GN,
Surmont DW, Goldman S, Mendlewicz J
Department of Psychiatry,
Erasme Hospital,
Free University of Brussels, Belgium.
Biol Psychiatry 1989 Jan 15; 25(2):141-52

ABSTRACT

Plasma norepinephrine (NE), free 3-methoxy-4-hydroxyphenethylene glycol (MHPG), and binding of tritiated yohimbine to platelet membranes were measured in 14 patients with generalized anxiety disorder (GAD), who were matched for age and sex with 14 patients with unipolar major depressive disorder (MDD) and 14 normal subjects. Plasma NE and MHPG levels were increased and the number of alpha2-adrenoreceptors (Bmax) was decreased in GAD patients compared with MDD and normal subjects. No differences were found between MDD patients and normal subjects for plasma NE, MHPG, and alpha2-adrenoreceptor binding. Plasma NE and MHPG were significantly correlated in MDD patients and tended toward a significant positive correlation in GAD patients. Plasma MHPG and affinity of binding platelet alpha2-adrenoreceptors (Kd) were significantly correlated in normal subjects. Thus, noradrenergic activity seems to be increased in patients with GAD, but not in patients with MDD. In GAD patients, higher levels of catecholamines may lead to a down-regulation of presynaptic alpha2-adrenoreceptors.

Options
Yohimbine
Noradrenaline
Anxiety resources
Sedative hypnotics
Subthreshold syndromes
Catecholamine depletion
Noradrenaline and anxiety
Noradrenaline and depression
Noradrenergic-selective agents
Noradrenaline and dopamine co-release
Noradrenaline and the hedonic properties of drugs

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family